ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

TRML Tourmaline Bio Inc

15,04
0,04 (0,27%)
18 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Tourmaline Bio Inc TRML NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,04 0,27% 15,04 01:06:26
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
15,00 14,64 15,45 15,04 15,00
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
16.5.202413:00GLOBETourmaline Bio Initiates Clinical Development of TOUR006 for..
13.5.202422:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.5.202413:15EDGAR2Form 8-K - Current report
13.5.202413:00GLOBETourmaline Bio Reports First Quarter 2024 Financial Results..
02.4.202413:00GLOBEAvalo Therapeutics Appoints Biotech Leaders to Board of..
19.3.202412:00GLOBETourmaline Bio Reports Fourth Quarter and Full Year 2023..
27.2.202413:30GLOBETourmaline Bio to Present at Upcoming Investor Conferences
15.2.202403:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15.2.202402:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09.2.202422:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01.2.202414:00GLOBETourmaline Bio to Present at the Guggenheim Healthcare Talks..
29.1.202422:01GLOBETourmaline Bio Announces Closing of $172.5 Million Public..
26.1.202422:12EDGAR2Form 8-K - Current report
26.1.202422:08EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25.1.202413:00GLOBETourmaline Bio Announces Pricing of Public Offering of..
25.1.202403:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
24.1.202423:10EDGAR2Form 8-K - Current report
24.1.202422:05GLOBETourmaline Bio Announces Proposed Public Offering of Common..
08.1.202415:19EDGAR2Form 8-K - Current report
08.1.202413:00GLOBETourmaline Bio Announces Expected Upcoming Key Milestones..
15.12.202322:00GLOBETourmaline Bio added to the NASDAQ Biotechnology Index
14.12.202314:27EDGAR2Form 8-K - Current report
14.12.202313:30GLOBETourmaline Bio Appoints Dr. Clay Siegall as Chairman of the..
30.11.202314:25EDGAR2Form 8-K - Current report
01.11.202313:00GLOBETourmaline Bio to Present at Upcoming Investor Conferences
24.10.202302:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202302:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202302:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202302:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202302:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202300:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
19.10.202323:37GLOBETourmaline Bio Announces Closing of Merger with Talaris..